AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Post-Mkt 06-26 16:24:51 EDT

7.38

+0.72

+10.81%

盘后7.26

-0.12-1.63%

16:24 EDT

High7.40	Low6.47	Vol15.40M
Open6.49	D1 Closing6.66	Amplitude13.96%
Mkt Cap2.25B	Tradable Cap1.50B	Total Shares305.26M
T/O109.27M	T/O Rate7.60%	Tradable Shares202.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":7.38,"timestamp":1782504000000,"preClose":6.66,"halted":0,"volume":15401025,"hourTrading":{"tag":"盘后","latestPrice":7.26,"preClose":7.38,"latestTime":"16:24 EDT","volume":24808,"amount":182581.323008,"timestamp":1782505447965,"change":-0.12,"changeRate":-0.01626,"amplitude":0.017615},"delay":0,"changeRate":0.10810810810810807,"floatShares":202749853,"shares":305264947,"eps":-0.480392,"marketStatus":"Post-Mkt","change":0.72,"latestTime":"06-26 16:24:51 EDT","open":6.49,"high":7.4,"low":6.47,"amount":109273629.79845,"amplitude":0.13964,"askPrice":7.32,"askSize":20,"bidPrice":7.26,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-0.480392,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782518400000},"marketStatusCode":4,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":6.66,"preHourTrading":{"tag":"盘前","latestPrice":6.49,"preClose":6.66,"latestTime":"09:29 EDT","volume":67065,"amount":439486.60235999996,"timestamp":1782480599999,"change":-0.17,"changeRate":-0.025526,"amplitude":0.022523},"postHourTrading":{"tag":"盘后","latestPrice":7.26,"preClose":7.38,"latestTime":"16:24 EDT","volume":24808,"amount":182581.323008,"timestamp":1782505447965,"change":-0.12,"changeRate":-0.01626,"amplitude":0.017615},"volumeRatio":1.782039,"impliedVol":1.057,"impliedVolPercentile":0.6335},"requestUrl":"/m/hq/s/ABCL/tweets","defaultTab":"tweets","newsList":[{"id":"2646438898","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2646438898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646438898?lang=en_us&edition=fundamental","pubTime":"2026-06-25 03:11","pubTimestamp":1782328264,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 12,052 calls trading, 3x expected, and implied vol increasing almost 7 points to 10...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644060514","title":"Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644060514","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644060514?lang=en_us&edition=fundamental","pubTime":"2026-06-20 18:20","pubTimestamp":1781950850,"startTime":"0","endTime":"0","summary":"On 17 June 2026, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, including US$56,000,000 in upfront payments and eligibility for very large potential milestones and tiered royalties.\nAn interesting aspect of this agreement is that Jazz receives exclusive, worldwide development and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/why-abcellera-biologics-abcl-is-up-55-after-new-jazz-t-cell","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/why-abcellera-biologics-abcl-is-up-55-after-new-jazz-t-cell","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085611","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085611?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:40","pubTimestamp":1781786435,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-amylyx-pharmaceuticals-inc-amlx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4585","XLV","BK4007","BK4139","LU0128526141.USD","XBI","BK4588","ABCL","HCSG","BK4137","LABU","BK4535","ZYME","BK4581","LU0029874061.USD","AMLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644437847","title":"Jazz Pharma, AbCellera ink antibody deal worth up to $876 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644437847","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644437847?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:42","pubTimestamp":1781696527,"startTime":"0","endTime":"0","summary":"Jazz Pharma, AbCellera ink antibody deal worth up to $876 millionJune 17 (Reuters) - Jazz Pharmaceuticals JAZZ.O has signed a research collaboration and licensing agreement with Canada's AbCellera ABC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P0T0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0109394709.USD","BK4533","BK4121","BK4532","BK4535","IE00BN0W2T93.GBP","LU0889565916.HKD","IE00BN0W2V16.EUR","ABCL","LU0823416689.USD","LU0154245673.USD","JAZZ","IE00BN0W2W23.USD","LU0154245756.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743145","title":"Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743145","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644743145?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:33","pubTimestamp":1781695980,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals and AbCellera agreed to a deal worth up to $876 million to discover and develop treatments for gastrointestinal cancers and other solid tumors.The agreement includes plans for preclinical research collaboration, options and licensing of T-cell engaging multispecific antibodies.AbCellera, which has a T-cell engager platform, will perform discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months.Jazz is granted an option in connection with each research program and, once it exercises its option, will have exclusive, global rights to develop and commercialize each program.AbCellera will receive $56 million in total upfront payments for the first two research programs, plus an additional $28 million due when the third program starts.If Jazz exercises its option for development, AbCellera will also be eligible to receive up to $792 million per program in option fees and development, regulatory and commercial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0823416689.USD","LU0154245673.USD","BK4533","LU0889565916.HKD","BK4535","LU0154245756.USD","ABCL","IE00BN0W2V16.EUR","JAZZ","BK4007","IE00BN0W2T93.GBP","LU0320765992.SGD","IE00BN0W2W23.USD","BK4121","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644435317","title":"Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2644435317","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644435317?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:14","pubTimestamp":1781694854,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) announced a preclinical research collaboration, option and license agreement to discover and devel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-abcellera-collaborate-for-tce-multispecific-antibodies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-abcellera-collaborate-for-tce-multispecific-antibodies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BN0W2T93.GBP","LU0154245673.USD","ABCL","IE00BN0W2W23.USD","BK4007","BK4121","BK4535","LU0320765992.SGD","BK4533","JAZZ","IE00BN0W2V16.EUR","LU0889565916.HKD","LU0823416689.USD","LU0109394709.USD","BK4532","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644197748","title":"Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644197748","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644197748?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:01","pubTimestamp":1781694068,"startTime":"0","endTime":"0","summary":"AbCellera entered a preclinical research collaboration with Jazz Pharmaceuticals to discover T-cell engaging multispecific antibodies for GI cancers and other solid tumors.AbCellera will run discovery and early research for two programs, with a commitment to start a third within 12 months.Jazz holds program-by-program options for exclusive worldwide development and commercialization, triggered by option exercise and an option fee.AbCellera will receive USD 56 million upfront for the first two programs, with another USD 28 million due when the third program starts.AbCellera is eligible for up to USD 792 million per program in option fees and milestones, with tiered royalties from mid-single digits to low double-digits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLxLybx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4121","LU0154245756.USD","ABCL","IE00BN0W2V16.EUR","BK4533","BK4532","LU0320765992.SGD","LU0154245673.USD","IE00BN0W2W23.USD","BK4535","JAZZ","LU0823416689.USD","BK4007","LU0109394709.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748912","title":"Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748912?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:00","pubTimestamp":1781694000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUACG2J1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4007","LU0109394709.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","LU0320765992.SGD","ABCL","BK4533","BK4532","JAZZ","LU0823416689.USD","LU0154245673.USD","LU0154245756.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748178","title":"Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748178?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:00","pubTimestamp":1781694000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUACG2J1Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4121","LU0154245756.USD","ABCL","IE00BN0W2V16.EUR","BK4533","BK4532","LU0320765992.SGD","LU0154245673.USD","IE00BN0W2W23.USD","BK4535","JAZZ","LU0823416689.USD","BK4007","LU0109394709.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748176","title":"Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748176?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:00","pubTimestamp":1781694000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUACG2J1Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4007","LU0109394709.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0889565916.HKD","IE00BN0W2V16.EUR","LU0320765992.SGD","ABCL","BK4533","BK4532","JAZZ","LU0823416689.USD","LU0154245673.USD","LU0154245756.USD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643729739","title":"Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643729739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643729739?lang=en_us&edition=fundamental","pubTime":"2026-06-13 02:24","pubTimestamp":1781288659,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. recently appointed Victor Sandor, M.D.C.M., a veteran oncology drug developer with experience at Array BioPharma, Incyte, Biogen, and AstraZeneca, to its Board of Directors as an independent director.\nSandor’s history of helping guide multiple oncology medicines through regulatory approval and his current roles on several biotech boards may influence how investors view AbCellera’s clinical and governance capabilities.\nWe’ll now examine how adding Sandor’s late-stage...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-using-boardroom-oncology-talent-to-redefin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-using-boardroom-oncology-talent-to-redefin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643943672","title":"AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2643943672","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643943672?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:12","pubTimestamp":1781280757,"startTime":"0","endTime":"0","summary":"Abcellera Biologics held its annual shareholder meeting on June 11, 2026.Investors backed the board’s nominees for Class III director seats, setting three-year terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7sHd0R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642236132","title":"AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2642236132","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642236132?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:50","pubTimestamp":1781200238,"startTime":"0","endTime":"0","summary":"AbCellera Biologics director Victor Sandor filed an initial Form 3 on June 11, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL5PRBk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641141474","title":"AbCellera Biologics Adds Victor Sandor to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2641141474","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641141474?lang=en_us&edition=fundamental","pubTime":"2026-06-06 00:30","pubTimestamp":1780677056,"startTime":"0","endTime":"0","summary":"AbCellera Biologics ( ($ABCL) ) just unveiled an announcement. On June 1, 2026, AbCellera Biologics appointed medical oncologist Victor Sandor to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-victor-sandor-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-victor-sandor-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143339","title":"AbCellera appoints Victor Sandor to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143339","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641143339?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:00","pubTimestamp":1780664450,"startTime":"0","endTime":"0","summary":"AbCellera appointed Victor Sandor, M.D.C.M., to its board as an independent director.Sandor was chief medical officer at Array BioPharma before its acquisition by Pfizer.He previously led global clinical development at Incyte, supporting the approval of Jakafi .Sandor also held senior oncology roles at Biogen, with earlier positions at AstraZeneca.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL5PhjlM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143888","title":"Abcellera Appoints DR. Victor Sandor to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143888","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641143888?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:00","pubTimestamp":1780664401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUAB6BZH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640186611","title":"Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640186611","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640186611?lang=en_us&edition=fundamental","pubTime":"2026-06-04 01:21","pubTimestamp":1780507263,"startTime":"0","endTime":"0","summary":"In recent months, AbCellera Biologics Inc. has seen analyst earnings estimates for the full year rise meaningfully, while its performance has surpassed the broader Medical sector and its Medical – Biomedical and Genetics peers.\nThis combination of a stronger earnings outlook and relative industry outperformance has drawn increased attention to AbCellera’s evolving business model and profit potential.\nWe’ll now examine how this stronger earnings outlook could influence AbCellera’s existing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-turning-upgraded-earnings-forecasts-into-a","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-turning-upgraded-earnings-forecasts-into-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911809","title":"A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640911809?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:16","pubTimestamp":1780391807,"startTime":"0","endTime":"0","summary":"Recent analyst reports highlight a more positive earnings outlook for AbCellera Biologics (ABCL). This coincides with the stock outperforming the broader Medical sector and its peers this year, which has influenced sentiment around its recent move.\nSee our latest analysis for AbCellera Biologics.\nThe recent 1 month share price return of 45.82% and 90 day share price return of 74.12% suggest momentum has been building, even though the 3 year total shareholder return is slightly down while the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-improved","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-improved","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637950319","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637950319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637950319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:40","pubTimestamp":1779450047,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","HIMY","BK4535","HMYY","HIMZ","BK4007","INDV","BK4121","HIMS","ABCL","HIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636731865","title":"AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636731865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636731865?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:01","pubTimestamp":1779213675,"startTime":"0","endTime":"0","summary":"AbCellera outlined a strategy shift toward advancing an internal pipeline of antibody medicines, supported by an integrated platform spanning discovery through clinical manufacturing and development.The company cited 20+ internal program starts, with 2 molecules in IND-enabling activities and 2 molecules in the clinic as of March 31, 2026.ABCL635, an NK3R-targeting GPCR antibody for moderate-to-severe menopausal vasomotor symptoms, is in Phase 2 with a topline readout expected in Q3 2026.ABCL575, an OX40L program in immunology and inflammation, is in Phase 1 with a topline readout expected in Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3K50px:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.2043},{"period":"1month","weight":0.259},{"period":"3month","weight":1.0367},{"period":"6month","weight":0.8603},{"period":"1year","weight":0.7526},{"period":"ytd","weight":0.9474}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.5,"avgChangeRate":0.112831},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}